LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
111.92
-1.39 (-1.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close113.31
Open112.88
Bid111.75 x 800
Ask111.92 x 1300
Day's Range110.66 - 113.36
52 Week Range73.69 - 116.61
Volume4,224,178
Avg. Volume4,163,963
Market Cap111.641B
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateOct 23, 2018
Forward Dividend & Yield2.25 (1.98%)
Ex-Dividend Date2018-11-14
1y Target Est111.63
Trade prices are not sourced from all markets
  • CNBC11 hours ago

    Cramer's lightning round: GoPro's stock could go higher on a 'good holiday season'

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. GoPro Inc. GPRO : "I think that GoPro's going to have a good holiday season.

  • BMY vs. LLY: Which Stock Should Value Investors Buy Now?
    Zacks21 hours ago

    BMY vs. LLY: Which Stock Should Value Investors Buy Now?

    BMY vs. LLY: Which Stock Is the Better Value Option?

  • Pfizer’s Dividends and Earnings Quality
    Market Realist21 hours ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist23 hours ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Pfizer’s Growth Rate and Estimates
    Market Realist2 days ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist2 days ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • Better Buy: GlaxoSmithKline plc vs. Eli Lilly
    Motley Fool2 days ago

    Better Buy: GlaxoSmithKline plc vs. Eli Lilly

    Which stock is a better bet in an uncertain market?

  • Reuters3 days ago

    Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
    Reuters3 days ago

    Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
    Investing.com3 days ago

    Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises

    Investing.com - Stocks in focus in pre-market trade Wednesday:

  • Investopedia3 days ago

    5 Blue Chip Drug Stocks Poised for Long-Term Gains

    Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.

  • Reuters4 days ago

    Minnesota accuses insulin makers of deceptive drug pricing

    Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively raising prices for insulin. In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002.

  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks4 days ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • How Nektar Therapeutics Is Positioned In October
    Market Realist4 days ago

    How Nektar Therapeutics Is Positioned In October

    Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.

  • Karen Walker Elected to Lilly Board of Directors
    PR Newswire4 days ago

    Karen Walker Elected to Lilly Board of Directors

    INDIANAPOLIS, Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee. Walker is the Senior Vice President and Chief Marketing Officer at Cisco where she has worked since 2009.

  • What’s Expected for Merck’s Q3 2018 Earnings
    Market Realist5 days ago

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.

  • Lilly Declares Fourth-Quarter 2018 Dividend
    PR Newswire5 days ago

    Lilly Declares Fourth-Quarter 2018 Dividend

    INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common ...

  • 3 Healthcare Stocks to Buy Amid the Carnage
    InvestorPlace5 days ago

    3 Healthcare Stocks to Buy Amid the Carnage

    My weekend scanning revealed relative strength emanating from healthcare stocks. For the brave souls who want to continue playing, I suggest looking for relative strength to buy. Here are three healthcare stocks to buy.

  • Eli Lilly’s IPO of Animal Health Company Is Getting ‘Ahead of Itself,’ Goldman Says
    Bloomberg5 days ago

    Eli Lilly’s IPO of Animal Health Company Is Getting ‘Ahead of Itself,’ Goldman Says

    While no analyst tracked by Bloomberg has yet rated Elanco a sell, the drugmaker for animals earned eight hold ratings, more than the five buys it received. While the company may benefit from a macro environment that includes increasing meat consumption and “humanization of pets,” Goldman Sachs analyst Jami Rubin said “the stock has gotten ahead of itself” after shares surged 36 percent through last week since a September listing at $24 per share. With the average analyst price target at $34.60, implying a return of less than 9 percent over the next twelve months, Elanco may be coming up short as investors draw comparisons to Zoetis Inc. Zoetis, the top company in medicines for pets and cattle, has seen its shares more than triple since their debut in 2013.

  • CNBC5 days ago

    Drugmakers will soon talk about price in ads — but not as explicitly as Trump administration wants

    Some drugmakers will soon tell consumers where they can see information about drug prices. Health and Human Services Secretary Alex Azar is expected on Monday to introduce a proposal that would require drugmakers to include the list price in their direct-to-consumer advertisements. This is a key piece of President Donald Trump's blueprint to lower drug prices.

  • Novartis’ Estimates and Recommendations on October 12
    Market Realist5 days ago

    Novartis’ Estimates and Recommendations on October 12

    Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).

  • Novartis: What to Expect from Q3 Earnings on October 18
    Market Realist5 days ago

    Novartis: What to Expect from Q3 Earnings on October 18

    Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.

  • New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
    PR Newswire5 days ago

    New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting

    - Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus ...

  • A Financial Overview of Bausch Health in October
    Market Realist8 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.